Clinical Trials
36 trialsXL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
DETERMINE
Cancer Research UK
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Thomas Jefferson University
ImmunoCobiVem
University Hospital, Essen
NEO-TIM
Fondazione Melanoma Onlus
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
RadioCoBRIM
Technische Universität Dresden
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
University Hospital Tuebingen
REPOSIT
Netherlands Working Group on Immunotherapy of Oncology
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Sunnybrook Health Sciences Centre
VEMUPLINT
Fondazione Melanoma Onlus
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
University of Pittsburgh
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
University of Louisville
VECODUE
Fondazione Melanoma Onlus
NEO-VC
University Hospital Tuebingen
The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
Icahn School of Medicine at Mount Sinai
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
University of California, San Francisco
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Abramson Cancer Center at Penn Medicine
Vemurafenib and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Grupo Español Multidisciplinar de Melanoma
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
M.D. Anderson Cancer Center
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Georgetown University
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Duke University
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
University of Arizona
ML28604
University of Iowa
12-107
University of Pittsburgh
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Melanoma Research Foundation Breakthrough Consortium
Radiation Use During Vemurafenib Treatment
University of Utah
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
Massachusetts General Hospital
Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Massachusetts General Hospital
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
Yale University
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BeyPro1
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
Memorial Sloan Kettering Cancer Center